Current and emerging treatment options for autoimmune hemolytic anemia

References

• Petz LD, Garratty G. Immune hemolytic anemias. 2nd ed. Philadelphia: Churchill Livingstone; 2004.
   Google Scholar
• Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood. 2014;124:2930–2936.
   PubMed Web of Science ®Google Scholar
• Fattizzo B, Zaninoni A, Nesa F, et al. Lessons from very severe, refractory, and fatal primary autoimmune hemolytic anemias. Am J Hematol. 2015;90:E149–E151.
   PubMed Web of Science ®Google Scholar
• Barcellini W, Zaninoni A, Fattizzo B, et al. Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from 8 Italian reference centers. Am J Hematol. 2018 Jul 7. DOI:10.1002/ajh.25212.
   Google Scholar
• Barcellini W. New insights in the pathogenesis of autoimmune hemolytic anemia. Transfus Med Hemother. 2015;42:287–293.
   PubMed Web of Science ®Google Scholar
• Hill QA, Stamps R, Massey E, et al. British society for haematology guidelines. Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia. Br J Haematol. 2017;177:208–220.
   PubMed Web of Science ®Google Scholar
• Salama A. Drug-induced immune hemolytic anemia. Expert Opin Drug Saf. 2009;8:73–79.
   PubMed Web of Science ®Google Scholar
• Garratty G, Arndt PA. Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007. Immunohematology. 2014;30:66–79.
   PubMedGoogle Scholar
• Zanella A, Barcellini W. Autoimmune hemolytic anemia. Hematologica. 2013;98(s3):252–255.
   Google Scholar
• Barcellini W. Current treatment strategies in autoimmune hemolytic disorders. Expert Rev Hematol. 2015;8(5):681–691.
   PubMed Web of Science ®Google Scholar
• Hill QA, Stamps R, Massey E, et al. British Society for Haematology. The diagnosis and management of primary autoimmune haemolytic anaemia. Br J Haematol. 2017;176:395–411.
   PubMed Web of Science ®Google Scholar
• Go RS, Winters JL, Kay NE. How I treat autoimmune hemolytic anemia. Blood. 2017;129(22):2971–2979.
   PubMed Web of Science ®Google Scholar
• Berentsen S. How I manage patients with cold agglutinin disease. Br J Haematol. 2018;181(3):320–330.
   PubMed Web of Science ®Google Scholar
• Berentsen S, Ulvestad E, Gjertsen BT, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004;103:2925–2928.
   PubMed Web of Science ®Google Scholar
• Berentsen S, Randen U, Vågan AM, et al. High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood. 2010;116:3180–3184.
   PubMed Web of Science ®Google Scholar
• Barcellini W, Zaja F, Zaninoni A, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biological studies. Blood. 2012;119:3691–3697.
   PubMed Web of Science ®Google Scholar
• Birgens H, Frederiksen H, Hasselbalch HC, et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol. 2013;163:393–399.
   PubMed Web of Science ®Google Scholar
• Berentsen S, Randen U, Oksman M, et al. Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial. Blood. 2017;130:537–541.
   PubMed Web of Science ®Google Scholar
• Michel M, Terriou L, Roudot-Thoraval F, et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). Am J Hematol. 2017;92:23–27.
   PubMed Web of Science ®Google Scholar
• Howard J, Hoffbrand AV, Prentice HG, et al. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura. Br J Haematol. 2002;117:712–715.
   PubMed Web of Science ®Google Scholar
• Miano M, Ramenghi U, Russo G. Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian association of paediatric haematology/oncology. Br J Haematol. 2016;175:490–495.
   PubMed Web of Science ®Google Scholar
• Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol. 2008;141:149–169.
   PubMed Web of Science ®Google Scholar
• Zaja F, Vianelli N, Volpetti S, et al. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2010;85:329–334.
   PubMed Web of Science ®Google Scholar
• Barcellini W, Zanella A. Rituximab therapy for autoimmune haematological diseases. Eur J Intern Med. 2011;22:220–229.
   PubMed Web of Science ®Google Scholar
• Mariette X, Rouanet S, Sibilia J, et al. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. Ann Rheum Dis. 2014;73:1508–1514.
   Google Scholar
• Visentini M, Tinelli C, Colantuono S, et al. Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: phase II clinical trial and systematic review. Autoimmun Rev. 2015;14:889–896.
   PubMed Web of Science ®Google Scholar
• Reynaud Q, Durieu I, Dutertre M, et al. Efficacy and safety of rituximab in auto-immune hemolytic anemia: a meta-analysis of 21 studies. Autoimmun Rev. 2015;14:304–313.
   PubMed Web of Science ®Google Scholar
• Maung SW, Leahy M, O’Leary HM, et al. A multi-center retrospective study of rituximab use in the treatment of relapsed or resistant warm hemolytic anemia. Br J Haematol. 2013;163:118–122.
   PubMed Web of Science ®Google Scholar
• Laribi K, Bolle D, Ghnaya H, et al. Rituximab is an effective and safe treatment of relapse in elderly patients with resistant warm AIHA. Ann Hematol. 2016;95:765–769.
   PubMed Web of Science ®Google Scholar
• Berentsen S, Ulvestad E, Langholm R, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica. 2006;91:460–466.
   PubMed Web of Science ®Google Scholar
• Gómez-Almaguer D, Solano-Genesta M, Tarín-Arzaga L, et al. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. Blood. 2010;116:4783–4785.
   PubMed Web of Science ®Google Scholar
• Manda S, Dunbar N, Marx-Wood CR, et al. Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia. Br J Haematol. 2015;170:734–736.
   PubMed Web of Science ®Google Scholar
• Cavazzini F, Lista E, Quaglia FM, et al. Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion. Leuk Lymphoma. 2016;57:2685–2688.
   PubMed Web of Science ®Google Scholar
• Galinier A, Delwail V, Puyade M. Ibrutinib is effective in the treatment of autoimmune haemolytic anaemia in mantle cell lymphoma. Case Rep Oncol. 2017;10:127–129.
   PubMed Web of Science ®Google Scholar
• Lacerda MP, Guedes NR, Yamakawa PE, et al. Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with del(17p). Ann Hematol. 2017;96:1577–1578.
   PubMed Web of Science ®Google Scholar
• Chiu H, Mallya S, Nguyen P, et al. The selective phosphoinoside-3-kinase p110δ inhibitor IPI-3063 potently suppresses B cell survival, proliferation, and differentiation. Front Immunol. 2017;8:747.
   PubMed Web of Science ®Google Scholar
• Puri KD, Gold MR. Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies. Front Immunol. 2012;3:256.
   PubMed Web of Science ®Google Scholar
• Ball J, Archer S, Ward S. PI3K inhibitors as potential therapeutics for autoimmune disease. Drug Discov Today. 2014;19:1195–1199.
   PubMed Web of Science ®Google Scholar
• Pleyer C, Wiestner A, Sun C. Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia. Leuk Lymphoma. 2018;15:1–9.
   Google Scholar
• Carson KR, Beckwith LG, Mehta J. Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib. Blood. 2010;115:915.
   PubMed Web of Science ®Google Scholar
• Danchaivijitr P, Yared J, Rapoport AP. Successful treatment of IgG and complement-mediated autoimmune hemolytic anemia with bortezomib and low-dose cyclophosphamide. Am J Hematol. 2011;86:331–332.
   PubMed Web of Science ®Google Scholar
• Hosoba S, Jaye DL, Cohen C, et al. Successful treatment of severe immune hemolytic anemia after allogeneic stem cell transplantation with bortezomib: report of a case and review of literature. Transfusion. 2015;55:259–264.
   PubMed Web of Science ®Google Scholar
• Rossi G, Gramegna D, Paoloni F, et al. Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study. Blood. 2018;132:547–550.
   PubMed Web of Science ®Google Scholar
• Wouters D, Zeerleder S. Complement inhibitors to treat IgM-mediated autoimmune hemolysis. Haematologica. 2015;100:1388–1395.
   PubMed Web of Science ®Google Scholar
• Meulenbroek EM, de Haas M, Brouwer C, et al. Complement deposition in autoimmune hemolytic anemia is a footprint for difficult-to-detect IgM autoantibodies. Haematologica. 2015;100:1407–1414.
   PubMed Web of Science ®Google Scholar
• Röth A, Bommer M, Hüttmann A. Complement inhibition with eculizumab in patients with cold agglutinin disease (CAD): results from a prospective Phase II trial (DECADE Trial). 57th Annual Meeting of the American Society of Hematology; 2015 Dec 3–6. Orlando, FL.
   Google Scholar
• Shi J, Rose EL, Singh A, et al. TNT003, an inhibitor of the, prevents complement activation induced by cold agglutinins. Blood. 2014;123:4015–4022.
   PubMed Web of Science ®Google Scholar
• Jaeger U, D’Sa S, Schoergenhofer C, et al. Long term efficacy, safety and PK/PD profile of the anti-C1s antibody (BIVV009) in primary cold agglutinin disease patients. 59th annual meeting of the American Society of Hematology; 2017 Dec 9–12; Atlanta, GA.
   Google Scholar
• Grossi FV, Bedwell P, Deschatelets P, et al. APL-2, a complement C3 inhibitor for the potential treatment of paroxysmal nocturnal hemoglobinuria (PNH): phase I data from two completed studies in healthy volunteers. 58th annual meeting of the American Society of Hematology; 2016 Dec 3–6; San Diego, CA.
   Google Scholar
• Gertz MA, Qiu H, Kendall L, et al. ANX005, an inhibitory antibody against C1q, blocks complement activation triggered by cold agglutinins in human disease. Blood. 2016;128:1265.
   Web of Science ®Google Scholar
• Risitano AM, Marotta S. Toward complement inhibition 2.0: next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2018;93:564–577.
   PubMed Web of Science ®Google Scholar
• Benamu E, Montoya JG. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis. 2016;29:319–329.
   PubMed Web of Science ®Google Scholar
• Zhou QN, Xing LM, Fu R, et al. Count and function of CD8(+)CXCR3(+) regulatory T cells in peripheral blood of patients with autoimmune hemolytic anemia. Zhonghua Yi Xue Za Zhi. 2011;91:1687–1690.
   PubMedGoogle Scholar
• Ahmad E, Elgohary T, Ibrahim H. Naturally occurring regulatory T cells and interleukins 10 and 12 in the pathogenesis of idiopathic warm autoimmune hemolytic anemia. J Investig Allergol Clin Immunol. 2011;21:297–304.
   PubMed Web of Science ®Google Scholar
• Ward FJ, Hall AM, Cairns LS, et al. Clonal regulatory T cells specific for a red blood cell autoantigen in human autoimmune hemolytic anemia. Blood. 2008;111:680–687.
   PubMed Web of Science ®Google Scholar
• Barcellini W, Clerici G, Montesano R, et al. In vitro quantification of anti-red blood cell antibody production in idiopathic autoimmune haemolytic anaemia: effect of mitogen and cytokine stimulation. Br J Haematol. 2000;111:452–460.
   PubMed Web of Science ®Google Scholar
• Toriani-Terenzi C, Fagiolo E. IL-10 and the cytokine network in the pathogenesis of human autoimmune hemolytic anemia. Ann N Y Acad Sci. 2005;1051:29–44.
   PubMed Web of Science ®Google Scholar
• Xu L, Zhang T, Liu Z, et al. Critical role of Th17 cells in development of autoimmune hemolytic anemia. Exp Hematol. 2012;40:994–1004.
   PubMed Web of Science ®Google Scholar
• Xu ZZ, Zhao BB, Xiong H, et al. Serum BAFF and APRIL levels in patients with autoimmune hemolytic anemia and their clinical significance. Int J Hematol. 2015;102:394–400.
   PubMed Web of Science ®Google Scholar
• Lenert A, Lenert P. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents. Drug Des Devel Ther. 2015;9:333–347.
   PubMed Web of Science ®Google Scholar
• Park JA, Lee HH, Kwon HS, et al. Sirolimus for refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: a case report and literature review of the treatment of post-transplant autoimmune hemolytic anemia. Transfus Med Rev. 2016;30:6–14.
   Google Scholar
• Jasinski S, Weinblatt ME, Glasser CL. Sirolimus as an effective agent in the treatment of immune thrombocytopenia (ITP) and Evans syndrome (ES): a single institution’s experience. J Pediatr Hematol Oncol. 2017;39:420–424.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Germing U, Götze KS, et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol. 2017;18:1338–1347.
   PubMed Web of Science ®Google Scholar
• Newland A, Lee EJ, McDonald V, et al. Fostamatinib for persistent/chronic adult immune thrombocytopenia. Immunotherapy. 2018;10:9–25.
   PubMed Web of Science ®Google Scholar
• Blumberg L, Humphries JE, Lasseter KC, et al. SYNT001: a humanized IgG4 monoclonal antibody that disrupts the interaction of FcRn and IgG for the treatment of IgG-mediated autoimmune diseases. 59th annual meeting of the American Society of Hematology; 2017 Dec 9–12; Atlanta, GA.
   Google Scholar
• Conley CL, Lippman SM, Ness P. Autoimmune hemolytic anemia with reticulocytopenia. A medical emergency. JAMA. 1980;244:1688–1990.
   PubMed Web of Science ®Google Scholar
• Van De Loosdrecht AA, Hendriks DW, Blom NR, et al. Excessive apoptosis of bone marrow erythroblasts in a patient with autoimmune hemolytic anemia with reticulocytopenia. Br J Hematol. 2000;108(2):313–315.
   PubMed Web of Science ®Google Scholar
• Naithani R, Agrawal N, Mahapatra M, et al. Autoimmune hemolytic anemia in children. Pediatr Hematol Oncol. 2007;24:309–315.
   PubMed Web of Science ®Google Scholar
• Aladjidi N, Leverger G, Leblanc T, et al. New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children. Hematologica. 2011;96:655–663.
   PubMed Web of Science ®Google Scholar
• Townsley DM, Winkler T. Nontransplant therapy for bone marrow failure. Hematology Am Soc Hematol Educ Program. 2016;2016(1):83–89.
   PubMedGoogle Scholar
• Khurana H, Malhotra P, Sachdeva MU, et al. Danazol increases T regulatory cells in patients with aplastic anemia. Hematology. 2018;8:1–5.
   Google Scholar
• Ziman A, Cohn C, Carey PM, et al. The Biomedical Excellence for Safer Transfusion (BEST) collaborative. Warm-reactive (immunoglobulin G) autoantibodies and laboratory testing best practices: review of the literature and survey of current practice. Transfusion. 2017;57:463–477.
   PubMed Web of Science ®Google Scholar
• Szczepiorkowski ZM, Winters JL, Bandarenko N, et al. Guidelines on the use of therapeutic apheresis in clinical practice–evidence-based approach from the apheresis applications committee of the American Society for apheresis. J Clin Apher. 2010;25:83–177.
   PubMed Web of Science ®Google Scholar
• Lecouffe-Desprets M, Néel A, Graveleau J, et al. Venous thromboembolism related to warm autoimmune hemolytic anemia: a case-control study. Autoimmun Rev. 2015;14:1023–1028.
   PubMed Web of Science ®Google Scholar
• Yusuf HR, Hooper WC, Grosse SD, et al. Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U.S. cohort of commercial insurance enrollees. Thromb Res. 2015;135:50–57.
   PubMed Web of Science ®Google Scholar
• Tsang M, Parikh SA. A concise review of autoimmune cytopenias in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2017;12:29–38.
   PubMed Web of Science ®Google Scholar
• Hauswirth AW, Skrabs C, Schutzinger C, et al. Autoimmune hemolytic anemias, Evans’ syndromes, and pure red cell aplasia in non‐Hodgkin lymphomas. Leuk Lymphoma. 2007;48:1139–1149.
   PubMed Web of Science ®Google Scholar
• Gentile M, Petrungaro A, Uccello G, et al. Venetoclax for the treatment of chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2017;26:1307–1316.
   PubMed Web of Science ®Google Scholar
• Lampson BL, Kasar SN, Matos TR, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016;128:195–203.
   PubMed Web of Science ®Google Scholar
• Rogers KA, Ruppert AS, Bingman A, et al. Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. Leukemia. 2016;30:346–350.
   PubMed Web of Science ®Google Scholar
• Karlsson C, Hansson L, Celsing F, et al. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia. 2007;21:511–514.
   PubMed Web of Science ®Google Scholar
• Osterborg A, Karlsson C, Lundin J. Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2009;4:47–53.
   PubMedGoogle Scholar
• Gomard‐Mennesson E, Ruivard M, Koenig M, et al. Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases. Lupus. 2006;15:223–231.
   PubMed Web of Science ®Google Scholar
• Alba P, Karim MY, Hunt BJ. Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus. 2003;12:633–635.
   PubMed Web of Science ®Google Scholar
• Lan L, Han F, Chen JH. Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta‐analysis. J Zhejiang Univ Sci B. 2012;13:731–744.
   PubMed Web of Science ®Google Scholar
• Ahn YS. Efficacy of danazol in hematologic disorders. Acta Haematol. 1990;84:122–129.
   PubMed Web of Science ®Google Scholar
• Akpek G, McAneny D, Weintraub L. Comparative response to splenectomy in Coombs‐positive autoimmune hemolytic anemia with or without associated disease. Am J Hematol. 1999;61:98–102.
   PubMed Web of Science ®Google Scholar
• Seve P, Bourdillon L, Sarrot‐Reynauld F, et al. DEF‐I Study Group. Autoimmune hemolytic anemia and common variable immunodeficiency: a case–control study of 18 patients. Medicine. 2008;87:177–184.
   PubMed Web of Science ®Google Scholar
• Gobert D, Bussel JB, Cunningham‐Rundles C, et al. Efficacy and safety of rituximab in common variable immunodeficiency‐associated immune cytopenias: a retrospective multicentre study on 33 patients. Br J Haematol. 2011;155:498–508.
   PubMed Web of Science ®Google Scholar
• Wong GK, Goldacker S, Winterhalter C, et al. Outcomes of splenectomy in patients with common variable immunodeficiency (CVID): a survey of 45 patients. Clin Exp Immunol. 2008;172:63–72.
   Google Scholar
• Ramakrishna R, Manoharan A. Auto‐immune haemolytic anaemia in ulcerative colitis. Acta Haematol. 1994;91:99–102.
   PubMedGoogle Scholar
• Leo Carnerero E, Aoufi S, Montero Cuadrado I, et al. Autoimmune hemolytic anemia associated with ulcerative colitis: response to infliximab. Am J Gastroenterol. 2009;104:2370–2371.
   PubMed Web of Science ®Google Scholar
• Daikeler T, Labopin M, Ruggeri A, et al. New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the autoimmune disease working party of the european group for blood and marrow transplantation. Blood. 2013;121:1059–1064.
   PubMed Web of Science ®Google Scholar
• Faraci M, Zecca M, Pillon M, et al. Autoimmune hematological diseases after allogeneic hematopoietic stem cell transplantation in children: an Italian multicenter experience. Biol Blood Marrow Transplant. 2014;20:272–278.
   PubMed Web of Science ®Google Scholar
• Wang M, Wang W, Abeywardane A, et al. Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: analysis of 533 adult patients who underwent transplantation at King’s College hospital. Biol Blood Marrow Transplant. 2015;21:60–66.
   PubMed Web of Science ®Google Scholar
• Holbro A, Abinun M, Daikeler T. Management of autoimmune diseases after haematopoietic stem cell transplantation. Br J Haematol. 2012;157:281–290.
   PubMed Web of Science ®Google Scholar
• Romero S, Solves P, Lancharro A, et al. Passenger lymphocyte syndrome in liver transplant recipients: a description of 12 cases. Blood Transfus. 2015;13:423–428.
   PubMed Web of Science ®Google Scholar
• Nishide S, Uchida J, Kabei K, et al. Passenger lymphocyte syndrome in the ABO-incompatible kidney transplant recipient receiving rituximab. Exp Clin Transplant. 2017. DOI:10.6002/ect.2016.0261.
   Google Scholar
• Garbe E, Andersohn F, Bronder E, et al. Drug induced immune haemolytic anaemia in the Berlin case-control surveillance study. Br J Haematol. 2011;154:644–653.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS One. 2016 Jul 29;11(7):e0160221.
   PubMed Web of Science ®Google Scholar
• Fattizzo B, Zaninoni A, Gianelli U, et al. Prognostic impact of bone marrow fibrosis and dyserythropoiesis in autoimmune hemolytic anemia. Am J Hematol. 2017;93:E88–E91.
   Web of Science ®Google Scholar
• Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical evolution of autoimmune cytopenias to idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and bone marrow failure syndromes. Am J Hematol. 2017;92:E26–E29.
   PubMed Web of Science ®Google Scholar